Advertisement

Cancer Immunology, Immunotherapy

, Volume 16, Issue 3, pp 182–185 | Cite as

Defective interleukin-1 production by monocytes from patients with malignant disease

Interferon increases IL-1 production
  • Jean Herman
  • Michael C. Kew
  • Arthur R. Rabson
Original Articles

Summary

Interleukin-1 (IL-1) production by monocytes of patients with various forms of malignant disease was measured after activating the cells with either lipopolysaccharide or malignant K562 cells. Monocytes from all the patients with large tumour masses, including 10 patients with hepatocellular carcinoma, produced considerably less IL-1 than controls or patients with small tumour burdens. After treating control or patient monocytes with human leucocyte interferon for 1 h prior to activation, IL-1 production was markedly improved. Depressed IL-1 production is, therefore, a further aberration in mononuclear function observed in patients with cancer.

Keywords

Carcinoma Cancer Research Interferon Hepatocellular Carcinoma Large Tumour 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Adams DO, Nathan CF (1983) Molecular mechanisms in tumour-cell killing by activated macrophages. Immunol Today 4:166Google Scholar
  2. 2.
    Arenzana-Seidedos F, Virelizier JL (1983) Interferons as macrophage-activating factors II. Enhanced secretion of Interleukin-1 by lipopolysaccharide-stimulated human monocytes. Eur J Immunol 13:437Google Scholar
  3. 3.
    Cameron DJ, Churchill WH (1979) Cytotoxicity of human macrophages for tumour cells. Enhancement by human lymphocyte mediators. J Clin Invest 63:977Google Scholar
  4. 4.
    Catalona WJ, Taylor PT, Rabson AS, Chretien PB (1972) A method for dinitrochlorbenzene contact sensitization. N Engl J Med 286:399Google Scholar
  5. 5.
    Dempsey RA, Dinarello CA, Mier JW, Rosenwasser LJ, Allegretta M, Brown TE, Parkinson DR (1982) The differential effects of human leukocyte pyrogen/lymphocyte activating factor, T cell growth factor, and interferon on human natural killer activity. J Immunol 129:2504Google Scholar
  6. 6.
    Hammerström J (1979) Human monocyte-mediated cytotoxicity to K562 cells: Activation by lymphokines. Scand J Immunol 10:575Google Scholar
  7. 7.
    Jett JR, Mantovani A, Herberman RB (1980) Augmentation of human monocyte-mediated cytolysis by interferon. Cell Immunol 54:425Google Scholar
  8. 8.
    Meltzer MS (1981) Macrophage activation for tumour cytotoxicity: Characterization of priming and trigger signals during lymphokine activation. J Immunol 127:179Google Scholar
  9. 9.
    Meltzer MS, Oppenheim JJ (1977) Bi-directional amplification of macrophage-lymphocyte interaction: Enhanced lymphocyte activation factor production by activated adherent mouse peritoneal cells. J Immunol 118:77Google Scholar
  10. 10.
    Meltzer MS, Stevenson MM (1978) Macrophage function in tumour bearing mice: Dissociation of phagocytic and chemotactic responsiveness. Cell Immunol 35:99Google Scholar
  11. 11.
    Moore RN, Oppenheim JJ, Farrar JJ, Carter CS, Waheed A, Shadduck RK (1980) Production of lymphocyte activating factor (Interleukin-1) by macrophages activated with colony-stimulating factors. J Immunol 125:1302Google Scholar
  12. 12.
    Oppenheim JJ, Gery I (1982) Interleukin-1 is more than an interleukin. Immunol Today 3:113Google Scholar
  13. 13.
    Pace JL, Russell SW (1981) Activation of mouse macrophages for tumour cell killing. 1. Quantitative analysis of interactions between lymphokine and lipopolysaccharide. J Immunol 126:1863Google Scholar
  14. 14.
    Pace JL, Russell SW, Torres BA, Johnson HN, Gray PW (1983) Recombinant mouse interferon induces the priming step in macrophage activation for tumour cell killing. J Immunol 130:2011PubMedGoogle Scholar
  15. 15.
    Sheagren JN, Block JB, Wolf SM (1967) Reticuloendothelial system phagocytic function in patients with Hodgkins disease. J Clin Invest 46:855Google Scholar
  16. 16.
    Stanwick TL, Campbell DE, Nahmias AJ (1980) Spontaneous cytotoxicity mediated by human monocyte macrophages against human fibroblasts infected with Herpes simplex augmentation by interferon. Cell Immunol 53:413Google Scholar
  17. 17.
    Unanue ER (1980) Co-operation between mononuclear phagocytes and lymphocytes in immunity. N Engl J Med 303:977Google Scholar
  18. 18.
    Vogel SN, Rosenstreich DL (1979) Defective Fc receptor-mediated phagocytosis in C3H-HeJ macrophages. 1. Correction by lymphokine-induced stimulation. J Immunol 123:2842Google Scholar
  19. 19.
    Vogel SN, Finebloom DS, English KE, Rosenstreich DL, Langreth SG (1983) Interferon-induced enhancement of macrophage Fc receptor expression: β interferon treatment of C3H-HeJ macrophages results in increased numbers and density of Fc receptors. J Immunol 130:1210Google Scholar

Copyright information

© Springer-Verlag 1984

Authors and Affiliations

  • Jean Herman
    • 1
    • 2
  • Michael C. Kew
    • 1
    • 2
  • Arthur R. Rabson
    • 1
    • 2
  1. 1.South African Medical Research Council Human Cellular Immunology UnitSchool of Pathology of the University of the WitwatersrandJohannesburgSouth Africa
  2. 2.S.A.I.M.R.JohannesburgSouth Africa

Personalised recommendations